LON:BXP Beximco Pharmaceuticals (BXP) Share Price, News & Analysis GBX 57.15 -4.70 (-7.59%) As of 03:19 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsNews and Trends About Beximco Pharmaceuticals Stock (LON:BXP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BXP alerts:Sign Up Key Stats Today's Range 57.15▼ 6050-Day Range 50▼ 64.8052-Week Range 35▼ 65Volume317 shsAverage Volume70,737 shsMarket Capitalization£254.95 millionP/E Ratio0.03Dividend Yield5.99%Price TargetN/AConsensus RatingN/A Company Overview Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Incorporated in 1976, the Company started its operation by importing products from Bayer, Germany and Upjohn, USA and selling them in the local market. In 1980, Beximco Pharma began manufacturing of these products under licensing arrangement and in 1983 launched its own formulation brands. Since its inception, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, nasal sprays, nebuliser solutions, sterile ophthalmic drops, insulins, injectables including prefilled syringes, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Brazil, among others and it has a geographic footprint in more than 50 countries. The Company has won the National Export (Gold) trophy for 5 times. It also won the highly prestigious SCRIP Award as the “Best Pharma Company in an Emerging Market” and also won CPhI Pharma Awards 2020 for “Innovation in Response to COVID-19.” In 2018, Beximco Pharma acquired majority stake in Nuvista Pharma (formerly Organon Bangladesh), a leading hormone and steroid manufacturer in the country. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world. For the year ended 30 June 2020, Beximco Pharma’s reported revenue was Bangladesh Taka ("BDT") 25,611.9m / £245.5m (12.3% growth) with reported profit after tax was BDT 3,544.4m / £34.0m (16.6% growth). For the half year ended 31 December 2020, Beximco Pharma’s reported revenue was Bangladesh Taka ("BDT") 14,400.2m / £125.8m (15.2% growth) with reported profit after tax was BDT 2,226.3m / £19.4m (29.8% growth). For more information, visit www.beximcopharma.com Read More Receive BXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beximco Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BXP Stock News HeadlinesBeximco Pharmaceuticals PLC - Depositary receipt price target decreased by 12.72% to 77.01 GBXOctober 20, 2026 | msn.comBeximco Pharma Clarifies Board Restructuring Reports Amid Ongoing BSEC DisputeSeptember 15, 2026 | tipranks.comThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.November 16 at 1:00 AM | Weiss Ratings (Ad)Beximco Pharmaceuticals PLC GDRAugust 1, 2026 | barrons.comDBA intervention saves BEXIMCO Pharma GDR from London delistingJune 27, 2026 | msn.comBeximco Pharma clears 2025 accounts, proposes cash dividend and eyes return to AIMJune 24, 2026 | tipranks.comBeximco Pharma lifts sales and profits on robust domestic growthJune 24, 2026 | tipranks.comBeximco Pharma Delivers Double-Digit Revenue and Profit Growth in First Half 2025-26June 24, 2026 | tipranks.comSee More Headlines BXP Stock Analysis - Frequently Asked Questions How have BXP shares performed this year? Beximco Pharmaceuticals' stock was trading at GBX 42 at the beginning of the year. Since then, BXP stock has increased by 36.1% and is now trading at GBX 57.15. How do I buy shares of Beximco Pharmaceuticals? Shares of BXP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolLON:BXP CIKN/A Webwww.beximco-pharma.com Phone+880-2-58611001FaxN/AEmployees5,500Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 1,939 Trailing P/E Ratio0.03 Forward P/E RatioN/A P/E GrowthN/ANet Income£970.84 billion Net Margins16.04% Pretax MarginN/A Return on Equity15.25% Return on Assets6.97% Debt Debt-to-Equity Ratio5.27 Current Ratio4.13 Quick Ratio0.37 Sales & Book Value Annual Sales£56.27 billion Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value£120.21 per share Price / Book0.00Miscellaneous Outstanding Shares446,112,000Free FloatN/AMarket Cap£254.95 million OptionableNot Optionable Beta0.25 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (LON:BXP) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredFDA clears next-gen therapy with 10 to 40 times greater potencyTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beximco Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Beximco Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.